secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2026-08-06T20:18:46+00:00
Accession:  0001104659-26-092037
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Q2 2026 net loss $3.9M; advances Phase 3 plan for DLB psychosis
--------------------------------------------------------------------------------

- Net loss of $3.9M ($0.04 per share) vs $6.7M loss in Q2 2025.
- R&D expenses fell to $5.1M from $11.5M; G&A $2.6M vs $2.5M.
- Cash $34.8M plus $21.6M grant funds; runway into Q4 2027.
- FDA meeting on Phase 3 trial for DLB psychosis; initiation planned for mid-2027.
- New composition of matter patent allowed for zervimesine extending protection to 2045.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926092037/0001104659-26-092037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926092037/tm2622462d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-092037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer